OnePin Peptide Library · Metabolic
Dulaglutide
Trulicity
Dulaglutide (brand name Trulicity) is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) developed by Eli Lilly for the treatment of type 2 diabetes mellitus. It consists of a GLP-1 analog covalently linked to a modified human IgG4 Fc fragment, which extends its half-life to approximately 5 days, allowing once-weekly subcutaneous dosing. It was FDA-approved in 2014.,Dulaglutide works by mimicking the incretin hormone GLP-1, which stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety. The AWARD clinical trial program demonstrated significant HbA1c reductions across multiple comparator studies. The REWIND cardiovascular outcomes trial (2019) showed that dulaglutide reduced major adverse cardiovascular events (MACE) in patients with type 2 diabetes, including those without established cardiovascular disease.,Dulaglutide is FDA-approved for improving glycemic control in type 2 diabetes and for reducing major cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. It is available in pre-filled single-dose pens at 0.75mg, 1.5mg, 3mg, and 4.5mg strengths.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Activates the GLP-1 receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion (incretin effect) while suppressing inappropriate glucagon release from alpha cells.,Slows gastric emptying, reducing the rate of glucose absorption from the gut and contributing to postprandial glucose control and increased satiety.,Centrally acts on hypothalamic appetite centers to reduce food intake. May also have direct cardioprotective effects including reduced inflammation, improved endothelial function, and decreased atherosclerosis progression.
Activates the GLP-1 receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion (incretin effect) while suppressing inappropriate glucagon release from alpha cells.,Slows gastric emptying, reducing the rate of glucose absorption from the gut and contributing to postprandial glucose control and increased satiety.,Centrally acts on hypothalamic appetite centers to reduce food intake. May also have direct cardioprotective effects including reduced inflammation, improved endothelial function, and decreased atherosclerosis progression.
What to expect
Weeks 1-2: Blood glucose improvements begin within days. GI side effects are most common during initiation. Appetite reduction often noticeable.
Evidence
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Keep separate
Pharmacokinetics
Storage. Store refrigerated at 2-8C. May be kept at room temperature (up to 30C) for up to 14 days if needed. Protect from light. Do not freeze.
Regulatory status
FDA-approved (2014) for type 2 diabetes glycemic control. Additional FDA indication (2020) for cardiovascular risk reduction in T2D. Also approved by EMA and regulatory agencies worldwide. Marketed as Trulicity by Eli Lilly.
Put it to work
Calculate, log & track
Open Dulaglutide straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Dulaglutide in the app →Go deeper
The guide & community
The complete Dulaglutide walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗